Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

997
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
997
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.2K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.2K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GDF15 (Growth/Differentiation Factor-15) Expression in Human Adipose Tissue and in Adipocyte Cell Lines.

Biomedicines·2026
Same author

Obesity- and Glucose-Dependent Differential Autophagy Marker Expression in Adipose Tissues and Adipocytes.

Obesity science & practice·2026
Same author

Oral losartan yields subtherapeutic airway exposure compared to nebulized delivery and fails to improve mucociliary clearance in cystic fibrosis.

Frontiers in pharmacology·2026
Same author

In-situ product recovery in microfluidic bioreactors.

Current opinion in biotechnology·2026
Same author

Establishment of a Single-Cell Minimal Medium: A Case Study for Microfluidic Cultivation of Corynebacterium glutamicum.

Biotechnology and bioengineering·2026
Same author

Age-Dependent Systemic Regulation of C1q/TNF-Related Protein 3 and Progranulin in Patients with Cystic Fibrosis: Biomarkers or Therapeutic Targets?

Biomedicines·2026

Related Experiment Video

Updated: Mar 30, 2026

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
08:42

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures

Published on: May 26, 2023

4.3K

Roflumilast partially reverses smoke-induced mucociliary dysfunction.

Andreas Schmid1, Nathalie Baumlin2, Pedro Ivonnet3

  • 1Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB #7058, Miami, FL, 33136, USA. aschmid2@med.miami.edu.

Respiratory Research
|November 2, 2015
PubMed
Summary

Roflumilast, a PDE4 inhibitor, reverses smoke-induced lung dysfunction by improving Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activity and ciliary function. This study highlights its potential in treating smoking-related respiratory issues.

More Related Videos

Methods for Detecting Cough and Airway Inflammation in Mice
04:33

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

1.5K
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
08:42

Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures

Published on: May 26, 2023

4.3K
Methods for Detecting Cough and Airway Inflammation in Mice
04:33

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

1.5K
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.8K

Area of Science:

  • Respiratory Medicine
  • Cell Biology
  • Pharmacology

Background:

  • Phosphodiesterases (PDEs) regulate intracellular cAMP, crucial for airway epithelial cell function.
  • PDE4 inhibitors, like roflumilast, can enhance Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activity by increasing cAMP.
  • Smoking and COPD impair mucociliary clearance (MCC) and CFTR function, but roflumilast's effects on smoke-induced dysfunction are underexplored.

Purpose of the Study:

  • To investigate the impact of roflumilast on cigarette smoke-induced mucociliary dysfunction in human bronchial epithelial cells.
  • To assess roflumilast's effects on cAMP levels, CFTR-mediated chloride conductance, airway surface liquid (ASL) volume, and ciliary beat frequency (CBF).

Main Methods:

  • Primary normal human bronchial epithelial cells (NHBE) cultured at air-liquid interface (ALI) were exposed to cigarette smoke.
  • Intracellular cAMP was measured using FRET; ASL volume by light refraction scanning; CBF by microscopy.
  • Chloride conductance was assessed in Ussing chambers, and CFTR expression quantified via qPCR.

Main Results:

  • Roflumilast increased intracellular cAMP and prolonged its elevation, particularly in smoke-exposed cells.
  • It improved smoke-induced reductions in CFTR-mediated chloride conductance and increased ASL volume.
  • Roflumilast rescued cigarette smoke-induced decreases in CBF, with enhanced effects when combined with formoterol.

Conclusions:

  • Roflumilast effectively rescues smoke-induced mucociliary dysfunction by restoring CFTR activity, increasing ASL volume, and stimulating CBF.
  • The combination of roflumilast and formoterol shows particular promise for enhancing ciliary function.
  • CFTR mRNA expression levels did not directly correlate with apical CFTR function in this model.